What is Annexon Retained Earnings?
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Annexon's retained earnings for the quarter that ended in Mar. 2024 was $-597.68 Mil.
Annexon's quarterly retained earnings
declined
from Sep. 2023 ($-544.61 Mil) to Dec. 2023 ($-572.50 Mil) and
declined
from Dec. 2023 ($-572.50 Mil) to Mar. 2024 ($-597.68 Mil).
Annexon's annual retained earnings
declined
from Dec. 2021 ($-296.32 Mil) to Dec. 2022 ($-438.26 Mil) and
declined
from Dec. 2022 ($-438.26 Mil) to Dec. 2023 ($-572.50 Mil).
Annexon Retained Earnings Calculation
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Annexon (NAS:ANNX) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Annexon (Annexon) Business Description
Traded in Other Exchanges
N/A
Address
1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
Executives
| Ted Yednock |
officer: EVP & Chief Innovation Officer |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| Muneer A Satter |
director |
C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611 |
| Jamie Dananberg |
officer: Chief Medical Officer |
3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
| Jennifer Lew |
officer: EVP & Chief Financial Officer |
2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710 |
| Michael Overdorf |
officer: EVP & Chief Business Officer |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| Bain Capital Life Sciences Fund, L.p. |
10 percent owner |
200 CLARENDON STREET, BOSTON MA 02116 |
| Douglas Love |
director, officer: President & CEO |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| Dean Richard Artis |
officer: EVP & Chief Scientific Officer |
C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005 |
| Bettina M. Cockroft |
director |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| Larry Mattheakis |
officer: Chief Scientific Officer |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| William D. Waddill |
director |
C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080 |
| Sanjay Keswani |
officer: EVP & Chief Medical Officer |
C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| William H. Carson |
director |
C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016 |
| Clarus Lifesciences Iii, L.p. |
10 percent owner |
101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
| James E Flynn |
10 percent owner, other: Possible Member of 10% Group |
780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANNX has been successfully added to your 